[A severe G6PD deficiency revealed during a chemotherapy protocol including rasburicase]

Ann Biol Clin (Paris). 2009 Jul-Aug;67(4):432-6. doi: 10.1684/abc.2009.0353.
[Article in French]

Abstract

We present here the case-report of a man with a severe G6PD deficiency revealed after the use of rasburicase (uricolytic drug) during a chemotherapy protocol. The genotypic analysis done to confirm the biochemical measurement revealed the 'Mediterranean mutation' at the hemizygous state (G6PD gene is located on chromosome X). Consequently to this diagnose, a search for G6PD deficiency has been performed (at the biochemical and genotypic levels) for the 9 children (7 daughters and 2 sons) of the proband. Surprisingly, one of his son was found to be hemizygous for the mediterranean mutation and one of his daughter appeared homozygous for this same mutation. This implies that the proband's wife (not studied) is certainly heterozygous for the mediterranean mutation, as it is very unlikely that this mutation had appeared de novo for two children of this couple.

Publication types

  • Case Reports
  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosomes, Human, Pair 10
  • Codon / genetics
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Glucosephosphate Dehydrogenase / blood*
  • Glucosephosphate Dehydrogenase / genetics
  • Glucosephosphate Dehydrogenase Deficiency / diagnosis*
  • Heterozygote
  • Homozygote
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Male
  • Middle Aged
  • Mutation
  • Pedigree
  • Prednisolone / administration & dosage
  • Vincristine / administration & dosage

Substances

  • Codon
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisolone
  • Glucosephosphate Dehydrogenase

Supplementary concepts

  • VAP-cyclo protocol